19 June 2018 : Clinical Research
Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell CarcinomaHongmin Chen1ABCE, Lei Zhou1CE, Yunli Yang12EF, Liuting Yang1DF, Long Chen12AG*
Med Sci Monit 2018; 24: CLR4183-4191
BACKGROUND: Chemoradiotherapy (CRT) is widely accepted and is considered a standard treatment, particularly for unresectable and inoperable esophageal squamous cell carcinoma (ESCC). However, the optimal use of the combined modalities of chemotherapy (CT) and radiotherapy (RT) remains controversial. In addition, no consensus has been reached regarding the exact efficacy of consolidation chemotherapy (CCT) and the most appropriate radiotherapy dose.
MATERIAL AND METHODS: Clinical data from 262 ESCC patients treated with CRT (n=165) or RT alone (n=97) were collected and reviewed. The long-term outcomes were analyzed, and treatment related acute toxicity reactions were compared.
RESULTS: The 1-year, 3-year, and 5-year overall survival (OS) rates were 75.3%, 35.6%, and 25.3%, respectively, for the CRT group and 61.5%, 26.7%, and 17.6% for the RT-alone group (P=0.015). The concurrent chemoradiotherapy (CCRT) and sequential chemoradiotherapy (SCRT) groups exhibited similar survival outcomes (for OS, P=0.568; for progression-free survival (PFS,) P=0.145). CCT after CCRT did not influence OS (P=0.236) but was associated with a more favorable PFS (P=0.020). In addition, high-dose of 60–65 Gy tended to prolong OS compared with low-dose (<60 Gy) or excessive-dose (>65 Gy). The incidence of adverse reactions, such as esophagitis and leukopenia, in the CRT group were significantly higher than in the RT-alone group (P=0.019, P=0.001, respectively), and no significant difference was observed between patients treated with CCRT and CCT after CCRT.
CONCLUSIONS: Treating non-surgical ESCC patients with CCRT conferred a significant survival benefit compared with RT alone. CCT after CCRT prolongs PFS but does not increase acute toxicity. High-dose (60–65 Gy) CCRT could generate more favorable survival outcomes.
Keywords: Carcinoma, Squamous Cell, chemoradiotherapy
01 September 2023 : EditorialEditorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2
Med Sci Monit 2023; 29:e942244
21 Sep 2023 : Clinical ResearchThe Impact of Implementing the Vortex Approach on Airway Management Performance in Stressed Medical Student...
Med Sci Monit In Press; DOI: 10.12659/MSM.940372
20 Sep 2023 : Clinical ResearchA Retrospective Study to Compare Pharyngeal Anatomical Changes Measured Before and After Treatment for Malo...
Med Sci Monit In Press; DOI: 10.12659/MSM.941749
20 Sep 2023 : Database AnalysisComparative Finite Element Analysis of Endocrowns and Traditional Restorations for Endodontically Treated M...
Med Sci Monit In Press; DOI: 10.12659/MSM.941314
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292